It’s tough for a man to know what to do following a diagnosis of prostate cancer.The treatment is often worse than the ...

RECIST criteria are inadequate for measuring ... For this reason, The Prostate Cancer Clinical Trials Working Group has defined radiological progression as the development of two or more lesions ...

The RECIST-evaluable patients included patients ... have been implicated as important in castration-resistant prostate cancer. Synergistic anti-tumor activity has been reported with the sequential ...

Prostate cancer, while commonly diagnosed as localized disease ... Randomization will be stratified by a number of characteristics including RECIST measurable disease vs bone-only disease and by prior ...

The RECIST guidelines are also reported hard to use with mesothelioma (given its particular growth characteristics), prostate cancer (the endpoint of tumour regression might not be applicable), in ...

The purpose of this study is determine objective response rate (ORR) by RECIST 1.1 by blinded independent central review (BICR) of envafolimab (cohort A), and of envafolimab combined with ipilimumab ...

Evidence of disease progression after prior therapy for prostate cancer: Disease progression after treatment ... new or progressive soft tissue masses on CT or MRI scans as defined by RECIST 1.1; ...

The deal sees Endocyte acquire an exclusive worldwide licence for ABX’s phase 3-ready prostate cancer candidate 177Lu ... in 40% to 60% of patients, and a RECIST response rate in soft tissue ...

(UroToday.com) The 2022 ESMO annual meeting featured a prostate cancer session, including a presentation by ... Study objectives were safety and preliminary efficacy assessed by PSA and RECIST ...